top of page

Journal: Clinics and Research in Hepatology and Gastroenterology

First author: Rim Bourguiba

Country of study: France and Tunisia

CEREMAIA Tenon author(s): Marion Delplanque, Catherine Grandpeix-Guyodo, Léa Savey, Sophie Georgin-Lavialle

Reference: Bourguiba R, Delplanque M, Grandpeix-Guyodo C, Boursier G, Savey L, Cuisset L, Georgin-Lavialle S. When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms? Clinics and Research in Hepatology and Gastroenterology. 2026;50:102820.

DOI: https://doi.org/10.1016/j.clinre.2026.102820


When to suspect monogenic autoinflammatory diseases in patients with digestive symptoms?

5 key points:

  • Some rare autoinflammatory diseases can cause abdominal pain, diarrhoea, digestive inflammation or symptoms that resemble inflammatory bowel disease.

  • Familial Mediterranean fever is the most common monogenic autoinflammatory disease and should be considered in people of Mediterranean origin with repeated inflammatory abdominal pain.

  • Associated signs such as recurrent fever, mouth ulcers, skin rashes, joint pain, macrocytic anaemia or family history should raise suspicion of an autoinflammatory cause.

  • Diagnosis is based on clinical assessment, inflammation markers, sometimes IL-18 measurement, and appropriate genetic testing.

  • Earlier diagnosis can reduce diagnostic delay, guide treatment and help prevent complications such as AA amyloidosis.


Introduction

Systemic autoinflammatory diseases are rare conditions caused by abnormal activation of the innate immune system, the body’s first line of defence. They can cause flares of inflammation with fever, pain, skin involvement, joint symptoms or digestive problems. In some patients, digestive symptoms are the main feature and may look like inflammatory bowel disease, such as Crohn’s disease.


Methods

This article is a narrative review of the medical literature. The authors describe the main monogenic autoinflammatory diseases that may cause digestive symptoms and highlight situations in which gastroenterologists should consider these diagnoses.


Results

Several diseases can cause abdominal pain, diarrhoea, colitis, digestive ulcers or inflammation that resembles Crohn’s disease. Familial Mediterranean fever is the most common, especially in people of Mediterranean origin. Other conditions include TRAPS, Mevalonate kinase deficiency, cryopyrin-associated diseases, VEXAS syndrome, A20 haploinsufficiency, and diseases linked to RIPK1, RELA, NFKB1, JAK1, STAT, PSTPIP1, ADA2, LACC1, XIAP or PLCG2. Warning signs include recurrent fever, unexplained inflammation in blood tests, mouth ulcers, skin rashes, joint pain, family history, Mediterranean origin, macrocytic anaemia or poor response to usual treatments for inflammatory digestive diseases.


Discussion

The article emphasizes that not all digestive inflammation should automatically be considered a typical bowel disease. An autoinflammatory disease may mimic inflammatory bowel disease, coexist with it, or be revealed by unusual digestive symptoms. Useful investigations may include inflammation markers, endoscopy, specific biomarkers such as IL-18, and above all appropriate genetic testing, ideally discussed with expert centres.


Conclusion

Rare autoinflammatory diseases should be considered when digestive symptoms are inflammatory, unexplained, recurrent or resistant to usual treatments. Early diagnosis can lead to more appropriate care, often using treatments that target inflammation, and may help prevent complications such as AA amyloidosis.


 
 
 

Article title: The effects of self-efficacy in managing the disease and disease adaptation levels of Familial Mediterranean

Fever (fmf) patients on satisfaction with life: a web-based cross-sectional study

First author: Demir RN

Journal: Orphanet Journal of Rare Diseases

Author of the abstract: Rim BOURGUIBA


L’impact de la confiance en soi sur la qualité de vie des personnes atteintes de Fièvre Méditerranéenne Familiale

Abstract

Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease in the world. It is characterized by recurrent inflammatory episodes of fever, abdominal pain, chest pain, and joint pain. Treatment is based on colchicine as first-line therapy, with biotherapy sometimes necessary. In addition to medical management, patients' ability to adapt to chronic disease and their sense of self-efficacy, defined as their feeling of personal effectiveness in managing the disease, can influence their quality of life. The objective of this study was to evaluate the impact of self-efficacy in FMF management and levels of adaptation to the disease on the satisfaction/quality of life of patients with FMF.


Methods:

A cross-sectional observational study was conducted using an online questionnaire distributed on Facebook and Instagram (FMF patient groups) between February and April 2024. The authors included adult Turkish patients (≥18 years old) who had been diagnosed at least one year prior.


The assessment tools used were:

- Self-Efficacy Scale for Chronic Disease (6 items).

- Adaptation to Chronic Illness Scale (25 items: physical, psychological, and social adaptation).

- Satisfaction With Life Scale.


Results

In this study of 423 adult Turkish patients with FMF, there was a predominance of females (73.8%), with ages ranging from 32 to 45 years. A disease duration of 21 years or more was reported in 38.3% of patients. The average self-efficacy score in disease management was relatively high (4.67/10). Adaptation to the disease was moderate overall (3.10/5), with better physical adaptation (3.36), followed by psychological adaptation (2.92) and social adaptation (2.87). Life satisfaction was below average (2.68/5). The correlation study revealed positive and significant associations between self-efficacy and adaptation (r = 0.532), between self-efficacy and life satisfaction (r = 0.417), and between adaptation and life satisfaction (r = 0.564) (Table 1). Regression analysis showed that self-efficacy explained 17.4% of the variance in life satisfaction, while adaptation to the disease explained 31.8%, confirming their decisive role in the self-management of FMF on quality of life (Table 2).


Conclusion

This study shows that in patients with FMF, self-efficacy and adaptation to the disease directly influence the overall low quality of life in this population. Strengthening therapeutic education and psychosocial support appears essential to improving the quality of life of adult patients with FMF.



Table 1: Correlation study between self-efficacy and quality of life in FMF patients

Étude de corrélation entre l’auto-efficacité et la qualité de vie chez les patients FMF

Table 2: Regression analysis of self-efficacy on quality of life and disease management

Analyse de régression de l’auto-efficacité sur la qualité de vie et la gestion de la maladie

 
 
 

First author: M. DELPLANQUE et al,

Journal: Liver International

Liver disease complicating Familial Mediterranean Fever:

Abstract:

Background: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV mutations. FMF patients can experience liver involvement, potentially leading to cirrhosis.

Objectives: This study aimed to evaluate liver involvement in FMF patients at a French tertiary center for adult FMF.


Methods: We conducted an observational study with FMF patients displaying 2 pathogenic MEFV mutations at the Adult National Reference Centre for Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA) in Paris and included in the JIR cohort. MEFV heterozygous patients and those with other liver disease causes were excluded.


Results: Among 533 FMF patients 12.4% had chronic liver abnormalities, with 30% who developed cirrhosis 54 years [36-57] in median after disease onset. Forty-seven percent were colchicine resistant, and 41% received interleukin-1 inhibitors. Cirrhotic patients experienced delayed hepatopathy diagnosis, prolonged FMF diagnosis delay, and late-onset treatment initiation compared to those with only liver function test abnormalities. Colchicine resistance and interleukin-1 inhibitor use were more common in cirrhotic patients. Body mass index and AA amyloidosis rates did not differ significantly between groups. Twenty-one patients undergone liver biopsies including 14 cirrhotic patients revealing steatohepatitis in 12 cases and probable steatohepatitis in 4. Other lesions, like iron overload and sinusoidal dilatation, were sporadically observed.


Conclusion: FMF patients are at risk of chronic liver disease. Regular liver function monitoring is crucial, particularly in case of persistent inflammation, due to the risk of progression to cirrhosis and its associated morbidity and mortality.


Lay Summary

More than, 10% of FMF patients develop chronic liver abnomalities over time and 4% cirrhosis. High-risk includes those with 2 MEFV mutations and colchicine resistance and chronic liver disease often begins after age 55 in FMF patients. In FMF patient with impaired liver function optimizing treatment targeting chronic inflammation is a key point in their care.

Liver biopsy of FMF patient

a. Liver biopsy with cirrhosis (sirius red staining)

b. Same liver biopsy with steatohepatitis associating steatosis, hepatocellular ballooning and inflammation (H&E staining)


Biopsie du foie d'un patient atteint de FMF
Biopsie du foie d'un patient atteint de FMF

Complications of cirrhosis in FMF patients

(A) Esophageal varices visualized by upper gastrointestinal endoscopy

(B) Hepatomegaly and ascite of a cirrhotic FMF patient detected in an abdominal CT scan

(C) Hepatomegaly and ascite of a cirrhotic FMF patient detected in an abdominal CT scan


Complications de la cirrhose chez les patients atteints de FMF
Complications de la cirrhose chez les patients atteints de FMF

Table 1. Demographic and clinical characteristics of the enrolled cohort.

Table 1. Demographic and clinical characteristics of the enrolled cohort.

Data are presented as median [Q1-Q3]. N= number of patients

†CRP C protein reactive, BMI Body Mass Index, FMF Familial Mediterranean fever, W women, M men



Table 4. Complication and Child Pugh Score of FMF patients with cirrhosis (n=20)

Table 4. Complication and Child Pugh Score of FMF patients with cirrhosis (n=20)

Transjugular intrahepatic portosystemic shunts (TIPS)

(% among cirrhotic patients)



 
 
 
bottom of page